THE WOODLANDS, Texas--(BUSINESS WIRE)--
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a company developing
personalized immunotherapies for autoimmune disorders, including
multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced
that the Company will report financial results for the three months
ended March 30, 2022 after the close of trading on Tuesday, May 12th.
The Company will also conduct a conference call and webcast to discuss
financial results and provide a corporate update at 4:30 P.M. EDT on
Tuesday, May 12th.
Conference Call and Webcast Details
To listen to the conference call, dial in approximately ten minutes
before the scheduled 4:30 P.M. time to 201-689-8040 or toll free at
877-407-8133. Please reference conference ID 13609081 or the Opexa
Therapeutics Earnings Call.
A live webcast of the call can also be accessed here
or via the webcast link on the Investor Relations page of Opexa's
website (www.opexatherapeutics.com).
An archive of the webcast will be available on the Company's website
until August 12, 2015.
There will be a brief Question & Answer session following management
commentary.
About Opexa
Opexa is a biopharmaceutical company developing a personalized
immunotherapy with the potential to treat major illnesses, including
multiple sclerosis (MS) as well as other autoimmune diseases such as
neuromyelitis optica (NMO). These therapies are based on Opexa’s
proprietary T-cell technology. The Company’s leading therapy candidate,
Tcelna®, is a personalized T-cell immunotherapy that is in a Phase IIb
clinical development program (the Abili-T trial) for the treatment of
secondary progressive MS. Tcelna consists of myelin-reactive T-cells,
which are expanded ex vivo from the patient’s peripheral blood and
reintroduced into the patient in an attenuated form via subcutaneous
injections. This process triggers a potent immune response against
specific subsets of autoreactive T-cells known to attack myelin for each
individual patient.
For more information, visit the Opexa Therapeutics website at www.opexatherapeutics.com.
Source: Opexa Therapeutics, Inc.